AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04536532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC121120 tablets
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study NCT04536532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC121120 placebo tablets
Description: single-Dose Study: Each dose of HEC121120 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~multiple-dose study/Patients with chronic hepatitis B:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study NCT04536532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir tablets
Description: Patients with chronic hepatitis B：Administered Entecavir orally once daily for consecutive 28 days in fasted state
Study NCT04536532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir placebo tablets
Description: Patients with chronic hepatitis B：Administered Entecavir placebo orally once daily for consecutive 28 days in fasted state
Study NCT02878486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jawbone Up
Description: Jawbone Up is a wrist wore water resistant activity monitor.
Study NCT02878486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Education
Description: A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
Study NCT02878486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Education
Description: A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
Study NCT02878486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivPAL
Description: Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
Study NCT02878486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActivPAL
Description: Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
Study NCT04428112 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Better Caregivers Workshop
Description: Workshops consist of small group or about 20-25 persons. Two peer co-facilitators (caregiver themselves) will guide workshop activities. Participants will receive a workshop booklet. Each week, participants will log on at least 2-3 times for a total time of approximately two hours. Participants do not require real time attendance at pre-determined times.
Study NCT04428112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will receive two brief 15-30 minutes phone calls by study staff, and will receive a handbook on dementia and caregiver resources while they wait for the workshop.
Study NCT04320121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nelutri™
Description: Nelutri™ 2,000 mg/day for 12 weeks
Study NCT04320121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo 2,000 mg/day for 12 weeks
Study NCT00892996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Metoclopramide 10 mg and dexamethasone 5 mg intravenous
Study NCT00892996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 5 mg
Description: Ondansetron 8 mg and dexamethasone 5 mg IV
Study NCT01051219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 milligrams to be taken orally, daily
Study NCT01051219 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Losartan
Description: 50 milligrams to be taken orally, daily
Study NCT05095545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV5080
Description: Hard gelatin capsules with a white body
Study NCT05095545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules with a white body
Study NCT02689050 — intervention group
Intervention type: DEVICE
Intervention: Needle based confocal laser endomicroscopy (nCLE)
Description: During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
Study NCT02603718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Study NCT00039130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
Study NCT00039130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Day 8 course II 50 mg/sq m IV infusion: d 8 course IV \& VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 1 g/sq m/day IV infusion Days 4 \& 5, courses II, IV, VI
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 10mg/sq m PO or IV Days 1-5 courses II-VII
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25 mg/sq m/day IV infusion Days 4 \& 5 courses III,V, VII
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 80 mg/sq m/day IV infusion Days 4 \& 5 courses II, IV, VI
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: 800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX \<10nM, courses II-VII
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 1.5 g/sq m IV infusion Day 1 courses II-VII
Study NCT04047914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial Photodynamic therapy
Description: Application 0.01% methylene blue with sterile swabs in each nostril with a 10-minute pre-irradiation~• Light-emitting diode (λ = 660 nm), for 300 seconds, with an irradiance of 400 mW / cm2
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75mg/m2 IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo1
Description: Placebo1 IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo2
Description: Placebo2 IV Q3W
Study NCT03802240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo2
Description: Placebo2 IV Q3W
Study NCT02685124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
Study NCT02685124 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange juice
Description: Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
Study NCT01352013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 (oil)
Description: 5ml daily with breakfast for 56 days.
Study NCT01352013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fatty Acids (placebo)
Description: 5ml daily with breakfast for 56 days.
Study NCT04151719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone bromide (MNTX)
Description: Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
Study NCT01148576 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: entecavir
Description: entecavir 0.5 mg qd for 12 months
Study NCT01148576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: entecavir 0.5 mg qd for 12 months
Study NCT01148576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: essentiale + entecavir
Description: entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
Study NCT03366155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 500 mg/m2, IV
Study NCT03366155 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SynchroMed II Pump
Description: implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60 mg/sq m PO/day Days 1-7 course I
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 2 mg IV push Day 1 courses II-VII
Study NCT00039130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: 300 mg/day PO Days 1-14, course I
Study NCT04047914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mupirocin ointment
Description: Performed with 2% Mupirocin Ointment, to be applied to the anterior nostrils twice a day for 5 days.
Study NCT03545035 — intervention group
Intervention type: DRUG
Intervention: idelalisib and rituximab
Description: patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
Study NCT02361294 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Study NCT02901964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hip Abductor Exercise
Description: 12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
Study NCT00908713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
Study NCT00908713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride 0.9% 10 mL every 12 h for 5 days
Study NCT04615481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elliptical Training Group
Description: The training program will be consisted of total 30 minutes of elliptical cross training (5 minutes warm up + Progressive Training up to 20 minutes of elliptical cross training + 5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
Study NCT04615481 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergo-metric Training Group
Description: The training program will be consisted of total 30 minutes of ergometric training (5 minutes warm up + Progressive Training up to 10 minutes of upper limb ergometric training + Progressive Training up to 10 minutes of lower limb ergometric training+5 minutes cool down) for 3 days in a week for 4 weeks at an average intensity of 50-70% the maximal heart rate according to ACSM guidelines.
Study NCT01148576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E + entecavir
Description: entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
Study NCT02901964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Aductor Exercise
Description: 12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
Study NCT04603235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manual-based Art Therapy
Description: This is a manual-based treatment and consists of 10 one-hour weekly sessions. The treatment consist of detailed guidelines based on phenomenological art therapy. The sessions follow the same structure: Introduction, short relaxation, art-making, reflections about the image, and conclusions. Examples of comprised art tasks; lifeline, emotional scribbles, and different roles. The art tasks served as a prompt for painting.
Study NCT04441710 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be invited to complete a detailed questionnaire to collect prospectively and retrospectively data around the CoViD19 serological screening.
Study NCT02520713 — intervention group
Intervention type: GENETIC
Intervention: Genetic testing and GAIN report
Description: All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
Study NCT01707095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unbundling of cords
Description: The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
Study NCT01707095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundling of cords
Description: The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
Study NCT04421612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-mestring (co-coping)
Description: 8 modules with the aim to reduce stress, increase coping of social isolation and coping with the consequences of reduced positive experiences
Study NCT02262676 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients treated by Physicians under approved local prescriptions
Study NCT04095793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ampreloxetine
Description: Oral tablet, QD
Study NCT02482649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EAA/T
Description: bi-weekly for 12weeks
Study NCT02482649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: dosage adjustment according to clinical effectiveness, QD for 12weeks
Study NCT02482649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
Study NCT01113788 — intervention group
Intervention type: DEVICE
Intervention: tricuspid isthmus imaging with Cartosound
Description: tricuspid isthmus imaging with Cartosound
Study NCT04144179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 1
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study NCT04144179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 2
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study NCT04144179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 3
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study NCT04144179 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent RIV with H3 strain 4
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study NCT04144179 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent RIV with 2018-2019 NH H3 strain
Description: Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
Study NCT03572062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation A
Description: RSV vaccine
Study NCT03572062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation B
Description: Adjuvanted RSV vaccine
Study NCT03572062 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation C
Description: RSV vaccine
Study NCT03572062 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00279305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD20 (rituximab)
Study NCT00279305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo intravenous infusion
Study NCT04303832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye exercises
Description: Eye exercises for correcting eye deviation
Study NCT04303832 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: eye glasses
Description: Eye glasses for correcting eye deviation
Study NCT04303832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eye glasses
Description: Eye glasses for correcting eye deviation
Study NCT00685672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenalin
Description: adrenalin 2 microgram pr ml placebo
Study NCT00272480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine/lamivudine
Study NCT00272480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT01675206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 supplementation
Study NCT00685672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Saline instead of adrenaline in the epidural mixture
Study NCT04053361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
Study NCT04053361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
Study NCT01013090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Study NCT01013090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Six percent hydroxyethyl starch
Description: Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
Study NCT05702736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: logotherapy-based intervention
Description: Logotherapy-based intervention was administered to the individuals in the intervention group as a total of eight sessions, once a week.
Study NCT01229280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Single dose 7.5 mg tablets of darifenacin
Study NCT01229280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: Single dose 7.5 mg tablets of Darifenacin
Study NCT04481854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cricoid pressure
Description: cricoid pressure during laryngoscopy
Study NCT04481854 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left paratracheal pressure
Description: left paratracheal pressure during laryngoscopy